Loading
Made mesothelin a drug target, from immunotoxins to ADCs and CAR-T, and leads NCI's mesothelioma programme.
Raffit Hassan is Chief of the Thoracic and GI Malignancies Branch at the National Cancer Institute. He is a thoracic oncologist known for making mesothelin a drug target, with work on mesothelin biology and mesothelin-directed agents including the immunotoxins SS1P and LMB-100 and the antibody-drug conjugate anetumab. His selected paper asks whether mesothelin immunotherapy for cancer is ready for prime time. He leads NCI's mesothelioma programme, and his work underpins current CAR-T and ADC efforts in mesothelioma and pancreatic cancer.
| Title | Journal | Year |
|---|---|---|
| Mesothelin immunotherapy for cancer: ready for prime time? | Journal of Clinical Oncology | 2016 |
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
Shares Mesothelin, Mesothelioma, National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares Mesothelin, Mesothelioma.